Satellite Symposia

Hear directly from industry in these popular one-hour presentations. Please check back as more symposia are added. Note: CE Credit is not offered for these Satellite Symposia. 

Saturday, February 26

8:45–9:30 am ET

      Clinical Value of Performing Cardiac PET with N-13 Ammonia 
                                      Sponsored by Ionetix Corporation

April Mann, MBA, CNMT, NCT, RT(N), FSNMMI-TS, VP, Clinical Development Ionetix Corporation
Peter Burke, VP, Sales & Marketing Ionetix Corporation

Program Description:
This presentation will provide an overview of the clinical value of performing Cardiac PET myocardial perfusion imaging with Myocardial Blood Flow compared to other non-invasive imaging options used to evaluate patients with known or suspected coronary artery disease. It will also review the clinical benefits of utilizing N-13 Ammonia for performing high quality imaging and discuss the options available for obtaining access to the tracer.

1:15–2:15 pm ET

Cerianna: Seeing Deeper into Recurrent and Metastatic Breast Cancer
Sponsored by GE Healthcare


Gary Ulaner, MD, PhD, FACNM 
James & Pamela Muzzy Endowed Chair in Molecular Imaging and Therapy, Hoag Family Cancer Institute 
Professor of Radiology, University of Southern California

Session Objectives:

  1. Learn about the clinical implications of Estrogen Receptor discordance 
  2. Understand the mechanism of Cerianna PET imaging
  3. Recognize the clinical applications of Cerianna PET imaging 
  4. Identify patients who may benefit from Cerianna PET imaging

The heterogeneity of recurrent or metastatic breast cancer may create challenges in making clinical decisions. Cerianna (F18 fluoroestradiol) injection may help clinicians with clinical decisions by detecting whole-body ER+ lesions. Participating in this discussion will help you to learn about the clinical implications of ER discordance, learn about the mechanism of action of Cerianna and how it is unique from another PET/CT radiopharmaceuticals used for recurrent or metastatic breast cancer, realize the clinical applications of Cerianna, and identify its benefits through case study reviews.

Sunday, February 27

1:15–2:15 pm ET

Artificial Intelligence Platform for Prostate Cancer Lesion Detection, Localization, and Tumor Burden Quantification using PSMA PET/CT
Sponsored by Lantheus

Nicholas G. Nickols, MD, PhD

Automated Prostate Molecular Imaging Standardized Evaluation (aPROMISE) is a software that employs deep learning technology to automate the segmentation of organs in low-dose CT images, quantifies the mean tracer uptake in the reference organs, and detects and segments regions of interest as potential pathological lesions in PSMA PET/CT. aPROMISE can assist in standardization of reporting and offers an automated, rapid, and quantitative analysis of disease burden.